Antiarrhythmics

A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data

Posted on by Kayla Korzekwinski

Journal of Pharmacokinetics and Pharmacodynamics • June 2018

Access article on PubMed.

Dallefeld SH, Atz AM, Yogev R, Sullivan JE, Al-Uzri A, Mendley SR, Laughon M, Hornik CP, Melloni C, Harper B, Lewandowski A, Mitchell J, Wu H, Green TP, Cohen-Wolkowiez M.

Amiodarone is a first-line antiarrhythmic for life-threatening ventricular fibrillation or ventricular tachycardia in children, yet little is known about its pharmacokinetics (PK) in this population. We developed a population PK (PopPK) model using samples collected via an opportunistic study design of children receiving amiodarone per standard of care supplemented by amiodarone PK data from the literature.

Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database

Posted on by Kayla Korzekwinski

Early Human Development • June 2015

Access article on PubMed.

Chu PY, Hill KD, Clark RH, Smith PB, Hornik CP

This study used data from a large clinical database to better understand current practices in Supraventricular tachycardia (SVT) management, safety of commonly used medications, and outcomes of hospitalized infants treated for SVT. Significant variation in SVT treatment and suboptimal outcomes warrant future clinical trials to determine best practices in treating SVT in infants.